CN113286633A - 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体 - Google Patents

用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体 Download PDF

Info

Publication number
CN113286633A
CN113286633A CN201980087139.5A CN201980087139A CN113286633A CN 113286633 A CN113286633 A CN 113286633A CN 201980087139 A CN201980087139 A CN 201980087139A CN 113286633 A CN113286633 A CN 113286633A
Authority
CN
China
Prior art keywords
cd123x
gene
patient
expression
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980087139.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·K·戴维森
S·丘奇
S·茹泰拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanotube Column Technology Co
Nottingham Trent University
Macrogenics Inc
Original Assignee
Nanotube Column Technology Co
Nottingham Trent University
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanotube Column Technology Co, Nottingham Trent University, Macrogenics Inc filed Critical Nanotube Column Technology Co
Priority to CN202411135807.6A priority Critical patent/CN119280393A/zh
Priority to CN202411135769.4A priority patent/CN119236065A/zh
Publication of CN113286633A publication Critical patent/CN113286633A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201980087139.5A 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体 Pending CN113286633A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202411135807.6A CN119280393A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体
CN202411135769.4A CN119236065A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752659P 2018-10-30 2018-10-30
US62/752,659 2018-10-30
US201862769078P 2018-11-19 2018-11-19
US62/769,078 2018-11-19
US201962878368P 2019-07-25 2019-07-25
US62/878,368 2019-07-25
PCT/US2019/058616 WO2020092404A1 (en) 2018-10-30 2019-10-29 Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202411135769.4A Division CN119236065A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体
CN202411135807.6A Division CN119280393A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体

Publications (1)

Publication Number Publication Date
CN113286633A true CN113286633A (zh) 2021-08-20

Family

ID=70464448

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201980087139.5A Pending CN113286633A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体
CN202411135769.4A Pending CN119236065A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体
CN202411135807.6A Pending CN119280393A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202411135769.4A Pending CN119236065A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体
CN202411135807.6A Pending CN119280393A (zh) 2018-10-30 2019-10-29 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体

Country Status (13)

Country Link
US (1) US20210395374A1 (enExample)
EP (1) EP3873606A4 (enExample)
JP (2) JP7551066B2 (enExample)
KR (1) KR102943465B1 (enExample)
CN (3) CN113286633A (enExample)
AU (1) AU2019371243A1 (enExample)
BR (1) BR112021008283A2 (enExample)
CA (1) CA3118081A1 (enExample)
IL (1) IL282827A (enExample)
MX (1) MX2021004868A (enExample)
SG (1) SG11202104367RA (enExample)
WO (1) WO2020092404A1 (enExample)
ZA (1) ZA202102775B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120866362A (zh) * 2025-07-15 2025-10-31 郑州大学第一附属医院 过表达ifitm2基因的car-t细胞、构建方法及其在免疫细胞疗法中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022025834A2 (pt) * 2020-06-18 2023-01-10 Macrogenics Inc Método para determinar se um paciente seria um respondedor adequado ao uso de uma molécula biespecífica cd123 x cd3 para tratar uma malignidade hematológica e método de tratamento de uma malignidade hematológica
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
TW202241469A (zh) * 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
WO2023092119A2 (en) * 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
EP4499683A1 (en) * 2022-03-29 2025-02-05 NGM Biopharmaceuticals, Inc. Ilt3 and cd3 binding agents and methods of use thereof
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
KR20250134857A (ko) * 2024-03-05 2025-09-12 사회복지법인 삼성생명공익재단 비소세포폐암 환자의 면역 관문 억제제에 대한 반응성을 예측하는 방법, 장치, 및 컴퓨터프로그램

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123442A1 (en) * 2009-10-08 2011-05-26 Pinku Mukherjee Tumor specific antibodies and uses therefor
WO2015069935A1 (en) * 2013-11-06 2015-05-14 Memorial Sloan-Kettering Cancer Center Compositions and methods for the treatment of acute myeloid leukemias and myelodysplastic syndromes
CN105873607A (zh) * 2013-08-23 2016-08-17 宏观基因有限公司 能够结合cd123和cd3的双特异性单价双抗体及其用途
US20170183413A1 (en) * 2014-03-19 2017-06-29 Cellectis Cd123 specific chimeric antigen receptors for cancer immunotherapy
WO2017214092A1 (en) * 2016-06-07 2017-12-14 Macrogenics, Inc. Combination therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005201935B2 (en) * 2004-05-06 2012-04-26 Veridex, Llc Prognostic for hematological malignancy
JP2018538247A (ja) 2015-10-23 2018-12-27 第一三共株式会社 Ａｍｌを処置することに用いるための医薬組成物およびそれを必要とする対象においてａｍｌを処置する方法
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123442A1 (en) * 2009-10-08 2011-05-26 Pinku Mukherjee Tumor specific antibodies and uses therefor
CN105873607A (zh) * 2013-08-23 2016-08-17 宏观基因有限公司 能够结合cd123和cd3的双特异性单价双抗体及其用途
WO2015069935A1 (en) * 2013-11-06 2015-05-14 Memorial Sloan-Kettering Cancer Center Compositions and methods for the treatment of acute myeloid leukemias and myelodysplastic syndromes
US20170183413A1 (en) * 2014-03-19 2017-06-29 Cellectis Cd123 specific chimeric antigen receptors for cancer immunotherapy
WO2017214092A1 (en) * 2016-06-07 2017-12-14 Macrogenics, Inc. Combination therapy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120866362A (zh) * 2025-07-15 2025-10-31 郑州大学第一附属医院 过表达ifitm2基因的car-t细胞、构建方法及其在免疫细胞疗法中的应用

Also Published As

Publication number Publication date
JP2024178163A (ja) 2024-12-24
JP7551066B2 (ja) 2024-09-17
CN119236065A (zh) 2025-01-03
KR20210110567A (ko) 2021-09-08
MX2021004868A (es) 2021-09-08
WO2020092404A1 (en) 2020-05-07
SG11202104367RA (en) 2021-05-28
BR112021008283A2 (pt) 2021-09-14
KR102943465B1 (ko) 2026-03-25
IL282827A (en) 2021-06-30
US20210395374A1 (en) 2021-12-23
EP3873606A4 (en) 2022-10-26
JP2022513402A (ja) 2022-02-07
EP3873606A1 (en) 2021-09-08
ZA202102775B (en) 2022-03-30
WO2020092404A8 (en) 2021-05-20
CA3118081A1 (en) 2020-05-07
CN119280393A (zh) 2025-01-10
AU2019371243A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CN113286633A (zh) 用于治疗血液系统恶性肿瘤的双特异性CD123 x CD3双抗体
AU2023201367B2 (en) Chimeric receptor T cell treatment using characteristics of the tumor microenvironment
US12583904B2 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
KR102416144B1 (ko) 환자에서 항-cd19 치료법의 치료 이익의 예측 방법
AU2022205653B2 (en) T cell therapy
JP2025003730A (ja) 癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法
RU2837616C2 (ru) БИСПЕЦИФИЧНЫЕ ДИАТЕЛА CD123 х CD3 ДЛЯ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКИХ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
KR20230030622A (ko) 혈액학적 악성 종양의 치료를 위한 이중특이적 CD123 x CD3 디아바디의 사용
US20260125449A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
HK40095144A (zh) 双特异性cd123 x cd3双抗体用於治疗血液系统恶性肿瘤的用途
HK40123134A (zh) 使用肿瘤微环境的特徵的嵌合受体t细胞治疗
HK40044133A (en) Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
HK40011995A (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210820

WD01 Invention patent application deemed withdrawn after publication